In a boost for AbbVie (ABBV), a U.S. International Trade Commission judge this week made an initial determination that sales of a competing version of its best-selling Botox treatment should be banned for 10 years.
The ruling came in response to a complaint filed last year by Allergan, which AbbVie has since acquired, that a pair of rival companies — Evolus (ELOS) and Daewoong Pharmaceuticals — allegedly stole trade secrets that were used to develop a new wrinkle-smoothing product. A final decision from the ITC, however, is not due until November.
About the Author Reprints
